Abstract
Background
The presence of hepatic portal venous gas (HPVG) is a rare finding. It is most commonly caused by bowel necrosis and typically carries a grave prognosis. Bevacizumab has emerged as an effective standard therapy in the frontline management of advanced non-small cell lung cancer (NSCLC). Although bevacizumab is associated with gastrointestinal perforation, it has not been shown to cause HPVG.
Case
A 75-year-old man, diagnosed with metastatic NSCLC, was treated with palliative chemotherapy consisting of paclitaxel, carboplatin, and bevacizumab for six cycles. He continued on maintenance bevacizumab after that for a total of six doses, given every 3 weeks, with continued stable disease. During a surveillance CT scan 4 weeks after the last dose of bevacizumab, HPVG was shown.
Conclusion
This is the first case of HPVG associated with bevacizumab therapy in a patient with metastatic NSCLC. The HPVG may have been an early warning sign of impending bowel perforation, and bevacizumab was immediately discontinued, with HPVG completely resolving on follow-up CT scan 2 weeks later. We recommend that bevacizumab therapy be immediately and permanently discontinued whenever HPVG is observed, as this may help avoid a potentially catastrophic outcome.
References
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550
Kung D, Ruan DT, Chan RK, Ericsson ML, Saund MS (2008) Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin. Dig Dis Sci 53:217–219
Zalinski S, Scatton O, Jacqmin S, Tacher V, Brézault C, Soubrane O (2009) Portal venous gas following chemotherapy for colorectal cancer liver metastasis. Eur J Surg Oncol 35:557–560
Kinoshita H, Shinozaki M, Tanimura H, Umemoto Y, Sakaguchi S, Takifuji K, Kawasaki S, Hayashi H, Yamaue H (2001) Clinical features and management of hepatic portal venous gas: four case reports and cumulative review of the literature. Arch Surg 136:1410–1414
Schindera ST, Triller J, Vock P, Hoppe H (2006) Detection of hepatic portal venous gas: its clinical impact and outcome. Emerg Radiol 12:164–170
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165–5171
Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186
Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19:577–582
Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G (2007) Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2:571–573
Jain RK (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29(Suppl 16):3–9
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147
Conflict of interest statement
The authors have no conflicts of interest or disclosures to report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ortega, J., Hayes, J.M. & Antonia, S. Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemother Pharmacol 65, 187–190 (2009). https://doi.org/10.1007/s00280-009-1104-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1104-8